Improved survival after unrelated donor bone marrow transplantation in children with primary immunodeficiency using a reduced-intensity conditioning regimen
Open Access
- 15 January 2005
- journal article
- clinical trial
- Published by American Society of Hematology in Blood
- Vol. 105 (2) , 879-885
- https://doi.org/10.1182/blood-2004-03-0960
Abstract
The optimal approach to stem cell transplantation in children with immunodeficiency who lack a matched family donor is controversial. Unrelated donor stem cell transplantation gives equivalent outcome to mismatched family donor stem cell transplantation in severe combined immunodeficiency, whereas unrelated donors may be preferable in non–severe combined immunodeficiency children. However, unrelated donor stem cell transplantation with conventional conditioning regimens has been associated with significant treatment-related toxicity, particularly in non–severe combined immunodeficiency patients with preexisting organ dysfunction. We report the outcome of a series of 33 consecutive unrelated donor transplantations performed at our center in children with primary immunodeficiency using a reduced-intensity conditioning regimen between 1998 and 2001. We have compared these outcomes with a retrospective control cohort of 19 patients who underwent transplantation with myeloablative conditioning between 1994 and 1998. All children in both groups had primary engraftment. There was no statistical difference in the speed of immune reconstitution or incidence of graft-versus-host disease between the 2 groups. Overall survival was significantly better in the reduced-intensity conditioning group: 31 (94%) of 33 patients survived, compared with 10 (53%) of 19 in the myeloablative conditioning group (P = .014). We conclude that the reduced-intensity conditioning regimen results in improved survival and reduced transplantation-related mortality compared with myeloablative conditioning in high-risk patients undergoing unrelated donor transplantation.Keywords
This publication has 22 references indexed in Scilit:
- Alemtuzumab (Campath-1H) in allogeneic stem cell transplantation: where do we go from here?Transplantation Proceedings, 2004
- Long-term survival and transplantation of haemopoietic stem cells for immunodeficiencies: report of the European experience 1968–99The Lancet, 2003
- Increased Thymic Output after Initiation of Antiretroviral Therapy in Human Immunodeficiency Virus Type 1–Infected Children in the Paediatric European Network for Treatment of AIDS (PENTA) 5 TrialThe Journal of Infectious Diseases, 2002
- High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitutionBlood, 2002
- A broad T-cell repertoire diversity and an efficient thymic function indicate a favorable long-term immune reconstitution after cord blood stem cell transplantationBlood, 2002
- Epstein–Barr virus-associated B cell lymphoproliferative disease after non-myeloablative allogeneic stem cell transplantationBone Marrow Transplantation, 1999
- Non-myeloablative ConditioningBone Marrow Transplantation, 1999
- Hematopoietic Stem-Cell Transplantation for the Treatment of Severe Combined ImmunodeficiencyNew England Journal of Medicine, 1999
- Immunophenotyping of blood lymphocytes in childhoodReference values for lymphocyte subpopulationsThe Journal of Pediatrics, 1997
- Severe combined immunodeficiency: treatment by bone marrow transplantation in 15 infants using HLA-haploidentical donorsEuropean Journal of Pediatrics, 1985